AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-21. (Canceled)

- 22. (Currently Amended) The A liposome encapsulating a water-soluble substance in an internal cavity thereof, wherein the liposome has a particle size of 300 nm or less, according to claim 1, which is manufactured by the following steps:
- (a) dissolving a phospholipid and a triglycerol phospholipid, a triglycerol, and cholesterol in a water-immiscible organic solvent, and mixing the resulting solution with an aqueous solution of a medicament, the water-soluble substance,
- (b) emulsifying the mixture to prepare a W/O emulsion with a particle size of 10 to 150 nm,
- (c) adding the W/O emulsion in an aqueous phase with stirring to form a double emulsion, and
 - (d) removing the organic solvent from the double emulsion.
- 23. (Previously Presented) The liposome according to claim 22, wherein the particle size of the W/O emulsion is 30 to 100 nm.

24. (Canceled)

- 25. (Withdrawn and Currently Amended) A method of producing <u>a liposome</u>, the liposome of claim 1, which comprises the following steps:
- (a) dissolving a phospholipid and a triglycerol phospholipid, a triglycerol, and cholesterol in a water-immiscible organic solvent, and mixing the resulting solution with an aqueous solution of a medicament, water-soluble substance,
- (b) emulsifying the mixture to prepare a W/O emulsion with a particle size of 10 to 150 nm,
- (c) adding the W/O emulsion in an aqueous phase with stirring to form a double emulsion, and

- (d) removing the organic solvent from the double emulsion, thereby producing a liposome encapsulating the water-soluble substance in an internal cavity thereof, wherein the liposome has a particle size of 300 nm or less.
- 26. (Withdrawn) The method according to claim 25, wherein the particle size of the W/O emulsion is 30 to 100 nm.

27. (Canceled)

- 28. (New) A liposome encapsulating a water-soluble substance in an internal cavity thereof, wherein the liposome has a particle size of 300 nm or less and contains a triglycerol and cholesterol.
- 29. (New) The liposome according to claim 22, which has a particle size of 200 nm or less.
- 30. (New) The liposome according to claim 22, wherein the water-soluble substance is a water-soluble low molecular weight compound, a protein, a nucleic acid, a polysaccharide, and/or an indicator.
- 31. (New) The liposome according to claim 22, wherein the water-soluble substance is a water-soluble low molecular weight compound and a polysaccharide.
- 32. (New) The liposome according to claim 22, wherein the water-soluble substance is a water-soluble low molecular weight compound.
- 33. (New) The liposome according to claim 30, wherein the water-soluble low molecular weight compound is nedaplatin, cisplatin, carboplatin, gemcitabine, or Ara-C.
- 34. (New) The liposome according to claim 30, wherein the polysaccharide is a chitosan derivative, or a polysaccharide having carboxyl group.

- 35. (New) The liposome according to claim 34, wherein the polysaccharide having carboxyl group is carboxymethylcellulose, hyaluronic acid, chondroitin, or chondroitin sulfate.
 - 36. (New) The liposome according to claim 22, wherein the triglycerol is triolein.
- 37. (New) The liposome according to claim 22, wherein the amount of triglycerol is 1 to 15 mol % based on the total lipids.
- 38. (New) The liposome according to claim 22, wherein a ligand and/or a water-soluble synthetic polymer is bound to a surface of the liposome.
- 39. (New) The liposome according to claim 22, wherein a ligand is bound to a surface of the liposome.
- 40. (New) The liposome according to claim 38, wherein the ligand has an affinity to a target cell or a target molecule.
- 41. (New) The liposome according to claim 38, wherein the ligand is an antibody or an antibody fragment.
- 42. (New) The liposome according to claim 38, wherein the water-soluble synthetic polymer is selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, and a copolymer of vinylpyrrolidone and maleic anhydride.
- 43. (New) The liposome according to claim 38, wherein the water-soluble synthetic polymer is polyalkylene glycol.
- 44. (New) The liposome according to claim 42, wherein the polyalkylene glycol is polyethylene glycol.
- 45. (New) The liposome according to claim 38, wherein the ligand and/or the water-soluble synthetic polymer binds only to an external surface of the liposome.

- 46. (New) A pharmaceutical composition containing the liposome according to claim 22.
- 47. (New) The liposome according to claim 28, which has a particle size of 200 nm or less.
- 48. (New) The liposome according to claim 28, wherein the water-soluble substance is a water-soluble low molecular weight compound, a protein, a nucleic acid, a polysaccharide, and/or an indicator.
- 49. (New) The liposome according to claim 28, wherein the water-soluble substance is a water-soluble low molecular weight compound and a polysaccharide.
- 50. (New) The liposome according to claim 28, wherein the water-soluble substance is a water-soluble low molecular weight compound.
- 51. (New) The liposome according to claim 48, wherein the water-soluble low molecular weight compound is nedaplatin, cisplatin, carboplatin, gemcitabine, or Ara-C.
- 52. (New) The liposome according to claim 48, wherein the polysaccharide is a chitosan derivative, or a polysaccharide having carboxyl group.
- 53. (New) The liposome according to claim 52, wherein the polysaccharide having carboxyl group is carboxymethylcellulose, hyaluronic acid, chondroitin, or chondroitin sulfate.
 - 54. (New) The liposome according to claim 28, wherein the triglycerol is triolein.
- 55. (New) The liposome according to claim 28, wherein the amount of triglycerol is 1 to 15 mol % based on the total lipids.
- 56. (New) The liposome according to claim 28, wherein a ligand and/or a water-soluble synthetic polymer is bound to surface of the liposome.

- 57. (New) The liposome according to claim 28, wherein a ligand is bound to surface of the liposome.
- 58. (New) The liposome according to claim 56, wherein the ligand has an affinity to a target cell or a target molecule.
- 59. (New) The liposome according to claim 56, wherein the ligand is an antibody or an antibody fragment.
- 60. (New) The liposome according to claim 56, wherein the water-soluble synthetic polymer is selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, and a copolymer of vinylpyrrolidone and maleic anhydride.
- 61. (New) The liposome according to claim 56, wherein the water-soluble synthetic polymer is polyalkylene glycol.
- 62. (New) The liposome according to claim 60, wherein the polyalkylene glycol is polyethylene glycol.
- 63. (New) The liposome according to claim 56, wherein the ligand and/or the water-soluble synthetic polymer binds only to an external surface of the liposome.
- 64. (New) A pharmaceutical composition containing the liposome according to claim 28.